Search

Your search keyword '"A. Martinez-Marti"' showing total 597 results
Start Over Author "A. Martinez-Marti"
597 results on '"A. Martinez-Marti"'

1. Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study

Author

Petracci, Elisabetta, Pasini, Luigi, Urbini, Milena, Felip, Enriqueta, Stella, Franco, Davoli, Fabio, Salvi, Maurizio, Beau-Faller, Michele, Tebaldi, Michela, Azzali, Irene, Canale, Matteo, Solli, Piergiorgio, Lai, Giulia, Amat, Ramon, Carbonell, Caterina, Falcoz, Pierre-Emmanuel, Martinez-Marti, Alex, Pencreach, Erwan, Delmonte, Angelo, Crinò, Lucio, and Ulivi, Paola

Published
2024
Full Text
View/download PDF

2. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

Author

Ospina, Aylen Vanessa, Bolufer Nadal, Sergio, Campo-Cañaveral de la Cruz, José Luis, González Larriba, Jose Luis, Macía Vidueira, Ivan, Massutí Sureda, Bartomeu, Nadal, Ernest, Trancho, Florentino Hernando, Álvarez Kindelán, Antonio, Del Barco Morillo, Edel, Bernabé Caro, Reyes, Bosch Barrera, Joaquim, Calvo de Juan, Virginia, Casal Rubio, Joaquin, de Castro, Javier, Cilleruelo Ramos, Ángel, Cobo Dols, Manuel, Dómine Gómez, Manuel, Figueroa Almánzar, Santiago, Garcia Campelo, Rosario, Insa Mollá, Amelia, Jarabo Sarceda, José Ramón, Jiménez Maestre, Unai, López Castro, Rafael, Majem, Margarita, Martinez-Marti, Alex, Martínez Téllez, Elisabeth, Sánchez Lorente, David, and Provencio, Mariano

Published
2024
Full Text
View/download PDF

3. Evaluation of Plantar Pressure Sensors for Classification of Ski Gear Using Deep Learning Models

Author

Polo-Rodríguez, Aurora, Martínez-Martí, Fernando, Marcen, Noel, Carvajal, Miguel A., Medina-Quero, Javier, Martínez-García, María Sofía, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Bravo, José, editor, Nugent, Chris, editor, and Cleland, Ian, editor

Published
2024
Full Text
View/download PDF

4. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer

Author

Ignacio I Wistuba, Amelia Insa, Mariano Provencio, Bartomeu Massutí, Federico Garrido, Edwin R Parra, Delvys Rodriguez-Abreu, Manuel Cobo, Joaquín Casal-Rubio, Ernest Nadal, Javier Martín-López, Diego Megías, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Isidoro Barneto Aranda, Santiago Viteri, Marta Casarrubios, Cristina Martinez-Toledo, Virginia Calvo, Marta Molina-Alejandre, Francisco Perea, Javier de Castro, Joaquín Mosquera Martínez, Rafael Muñoz-Viana, Natalia Aptsiauri, and Francisco Ruiz-Cabello

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on perioperative chemoimmunotherapy (ChIO) efficacy or response mechanisms in the context of HLA class I defects.Methods Baseline HLA class I tumor status (HLA-deficient (HLA-DEF) or HLA-proficient (HLA-PRO)) was determined by DNA LOH combined with immunohistochemistry for protein levels in tissue of 24 patients with NSCLC treated with perioperative nivolumab plus chemotherapy from NADIM trial (NCT03081689). We integrated HLA tumor status with molecular data (programmed death-ligand 1 (PD-L1), TMB, TCR repertoire, TILs populations, bulk RNA-seq, and spatial transcriptomics (ST)) and clinical outcomes (pathological response and survival data) to study the activity of perioperative ChIO considering HLA class I defects.Results HLA-DEF tumors comprised 41.7% of analyzed tumors and showed a desert-like microenvironment at baseline, with lower PD-L1 levels and reduced immune infiltrate. However, perioperative ChIO induced similar complete pathological response (CPR) rates in both HLA-DEF and PRO tumors (50% and 60% respectively, p=0.670), as well as 3-year survival rates: Progression-free survival (PFS) and overall survival (OS) of 70% (95% CI 32.9% to 89.2%) for HLA-DEF, and PFS 71.4% (95% CI 40.6% to 88.2%) and OS 92.9% (95% CI 59.1% to 99.0%) for HLA-PRO (log-rank PFS p=0.909, OS p=0.137). Proof-of-concept ST analysis of a CPR HLA-DEF tumor after ChIO showed a strong immune response with tertiary lymphoid structures (TLS), CD4+T cells with HLA class II colocalization, and activated CD8+T cells.Conclusions Our findings highlight the activity of perioperative ChIO, and the potential role of TLS and T-cell immune response, in NSCLC HLA-DEF tumors.

Published
2024
Full Text
View/download PDF

5. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Author

Mirallas, Oriol, Martin-Cullell, Berta, Navarro, Víctor, Vega, Kreina Sharela, Recuero-Borau, Jordi, Gómez-Puerto, Diego, López-Valbuena, Daniel, Salva de Torres, Clara, Andurell, Laura, Pedrola, Anna, Berché, Roger, Palmas, Fiorella, Ucha, José María, Villacampa, Guillermo, Rezqallah, Alejandra, Sanz-Beltran, Judit, Bach, Rafael, Bueno, Sergio, Viaplana, Cristina, Molina, Gaspar, Hernando-Calvo, Alberto, Aguilar-Company, Juan, Roca, María, Muñoz-Couselo, Eva, Martínez-Martí, Alex, Alonso, Ada, Eremiev, Simeon, Macarulla, Teresa, Oaknin, Ana, Saura, Cristina, Élez, Elena, Felip, Enriqueta, Peñuelas, Ángeles, Burgos, Rosa, Pardo, Patricia Gómez, Garralda, Elena, Tabernero, Josep, Serradell, Sònia, Servitja, Sònia, Paez, David, Dienstmann, Rodrigo, and Carles, Joan

Published
2024
Full Text
View/download PDF

6. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Author

Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García Campelo, Rosario, Casal, Joaquín, Dómine, Manuel, Massuti, Bartomeu, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, de Castro, Javier, Gómez de Antonio, David, Macia, Iván, Figueroa, Santiago, Fernández Vago, Luís, Calvo, Virginia, Palmero, Ramón, Sierra-Rodero, Belén, Martínez-Toledo, Cristina, Molina-Alejandre, Marta, Serna-Blasco, Roberto, Romero, Atocha, and Cruz-Bermúdez, Alberto

Published
2024
Full Text
View/download PDF

7. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, Zurawski, Bogdan, Spicer, Jonathan D, Garassino, Marina C, Majem, Margarita, Martinengo, Gastón L, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, and Samkari, Ayman

Published
2024
Full Text
View/download PDF

8. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Author

Provencio, Mariano, Robado de Lope, Lucía, Serna-Blasco, Roberto, Nadal, Ernest, Diz Tain, Pilar, Massuti, Bartomeu, González-Larriba, José Luis, Insa, Amelia, Sánchez-Hernández, Alfredo, Casal-Rubio, Joaquín, García-Campelo, Rosario, Sequero López, Silvia, Rogado, Jacobo, Martínez-Martí, Alex, Bosch-Barrera, Joaquim, Bernabé, Reyes, Vázquez Estévez, Sergio, Ponce, Santiago, de Castro, Javier, Coves Sarto, Juan, Reguart, Noemí, Dómine, Manuel, Aguilar, Andrés, Majem, Margarita, Estival, Anna, Peña Cabia, Silvia, López Martín, Ana, Sala González, María Ángeles, Cobo, Manuel, Camps, Carlos, Barneto, Isidoro, Calvo, Virginia, Collazo-Lorduy, Ana, Cruz-Bermúdez, Alberto, and Romero, Atocha

Published
2024
Full Text
View/download PDF

11. Activism Mobilizing Science Revisited

Author

Conde, Marta, Orta-Martínez, Martí, Turner, R. Kerry, Series Editor, Costanza, Robert, Series Editor, Farley, Joshua, Series Editor, Villamayor-Tomas, Sergio, editor, and Muradian, Roldan, editor

Published
2023
Full Text
View/download PDF

14. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Author

Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., and Brahmer, Julie R.

Published
2023
Full Text
View/download PDF

16. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Author

Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, and Thomas Birkballe Hansen

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleural mesothelioma (MPM) may improve treatment outcomes.Methods In this open-label, randomized study, patients with unresectable MPM received intratumoral ONCOS-102 (3×1011 virus particles on days 1, 4, 8, 36, 78, and 120) and pemetrexed plus cisplatin/carboplatin (from day 22), or pemetrexed plus cisplatin/carboplatin alone. The primary endpoint was safety. Overall survival (OS), progression-free survival, objective response rate, and tumor immunologic activation (baseline and day 36 biopsies) were also assessed.Results In total, 31 patients (safety lead-in: n=6, randomized: n=25) were enrolled. Anemia (15.0% and 27.3%) and neutropenia (40.0% and 45.5%) were the most frequent grade ≥3 adverse events (AEs) in the ONCOS-102 (n=20) and chemotherapy-alone (n=11) cohorts. No patients discontinued ONCOS-102 due to AEs. No statistically significant difference in efficacy endpoints was observed. There was a numerical improvement in OS (30-month OS rate 34.1% vs 0; median OS 20.3 vs 13.5 months) with ONCOS-102 versus chemotherapy alone in chemotherapy-naïve patients (n=17). By day 36, ONCOS-102 was associated with increased T-cell infiltration and immune-related gene expression that was not observed in the control cohort. Substantial immune activation in the tumor microenvironment was associated with survival at month 18 in the ONCOS-102 cohort.Conclusions ONCOS-102 plus pemetrexed and cisplatin/carboplatin was well tolerated by patients with MPM. In injected tumors, ONCOS-102 promoted a proinflammatory environment, including T-cell infiltration, which showed association with survival at month 18.

Published
2023
Full Text
View/download PDF

17. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Author

Mazieres, J, Drilon, A, Lusque, A, Mhanna, L, Cortot, AB, Mezquita, L, Thai, AA, Mascaux, C, Couraud, S, Veillon, R, Van den Heuvel, M, Neal, J, Peled, N, Früh, M, Ng, TL, Gounant, V, Popat, S, Diebold, J, Sabari, J, Zhu, VW, Rothschild, SI, Bironzo, P, Martinez-Marti, A, Curioni-Fontecedro, A, Rosell, R, Lattuca-Truc, M, Wiesweg, M, Besse, B, Solomon, B, Barlesi, F, Schouten, RD, Wakelee, H, Camidge, DR, Zalcman, G, Novello, S, Ou, SI, Milia, J, and Gautschi, O

Subjects
Lung, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lung Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Oncogenes, Programmed Cell Death 1 Receptor, Progression-Free Survival, Registries, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, immunotherapy, lung cancer, oncogenic addiction, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAnti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.Patients and methodsWe conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.ResultsWe studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Published
2019

18. Implementing a Blockchain-Based Security System Applied to IoT

Author

Martínez, Martí Miquel, Marín-Tordera, Eva, Masip-Bruin, Xavi, Sánchez-López, Sergio, García, Jordi, Akan, Ozgur, Editorial Board Member, Bellavista, Paolo, Editorial Board Member, Cao, Jiannong, Editorial Board Member, Coulson, Geoffrey, Editorial Board Member, Dressler, Falko, Editorial Board Member, Ferrari, Domenico, Editorial Board Member, Gerla, Mario, Editorial Board Member, Kobayashi, Hisashi, Editorial Board Member, Palazzo, Sergio, Editorial Board Member, Sahni, Sartaj, Editorial Board Member, Shen, Xuemin (Sherman), Editorial Board Member, Stan, Mircea, Editorial Board Member, Jia, Xiaohua, Editorial Board Member, Zomaya, Albert Y., Editorial Board Member, Gao, Honghao, editor, J. Durán Barroso, Ramón, editor, Shanchen, Pang, editor, and Li, Rui, editor

Published
2021
Full Text
View/download PDF

19. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Author

Wakelee, Heather A., primary, Altorki, Nasser K., additional, Zhou, Caicun, additional, Csőszi, Tibor, additional, Vynnychenko, Ihor O., additional, Goloborodko, Oleksandr, additional, Rittmeyer, Achim, additional, Reck, Martin, additional, Martinez-Marti, Alex, additional, Kenmotsu, Hirotsugu, additional, Chen, Yuh-Min, additional, Chella, Antonio, additional, Sugawara, Shunichi, additional, Fu, Chenqi, additional, Ballinger, Marcus, additional, Deng, Yu, additional, Srivastava, Minu K, additional, Bennett, Elizabeth, additional, Gitlitz, Barbara Jenifer, additional, and Felip, Enriqueta, additional

Published
2024
Full Text
View/download PDF

20. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Author

Felip, Enriqueta, Altorki, Nasser, Zhou, Caicun, Csőszi, Tibor, Vynnychenko, Ihor, Goloborodko, Oleksandr, Luft, Alexander, Akopov, Andrey, Martinez-Marti, Alex, Kenmotsu, Hirotsugu, Chen, Yuh-Min, Chella, Antonio, Sugawara, Shunichi, Voong, David, Wu, Fan, Yi, Jing, Deng, Yu, McCleland, Mark, Bennett, Elizabeth, Gitlitz, Barbara, and Wakelee, Heather

Published
2021
Full Text
View/download PDF

23. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Author

Amelia Insa, Mariano Provencio, Bartomeu Massutí, Margarita Majem, Delvys Rodriguez-Abreu, Manuel Cobo, Manuel Dómine, Ernest Nadal, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Javier De Castro Carpeño, Guillermo López Vivanco, Edel Del Barco, Nuria Viñolas, Isidoro Barneto Aranda, Marta Casarrubios, Atocha Romero, Reyes Bernabe, María del Rosario García-Campelo, Martín Lázaro-Quintela, Cristina Martinez-Toledo, Ismael Fernández-Miranda, Roberto Serna-Blanco, and Virginia Calvo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery.Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes.Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC) >0.9 for CPR prediction. A greater effect of neoadjuvant therapy was also seen in CPR tumors with a reduction of tumor markers and IFNγ signaling after treatment. Additionally, the higher expression of several genes, including AKT1, BST2, OAS3, or CD8B; or higher dendritic cells and neutrophils proportions in post-treatment non-CPR samples, were associated with relapse after surgery. Also, high pretreatment PD-L1 and tumor mutational burden levels influenced the post-treatment immune landscape with the downregulation of proliferation markers and type I interferon signaling molecules in surgery samples.Conclusions Our results reinforce the differences between CPR and non-CPR responses, describing possible response and relapse immune mechanisms, opening the possibility of therapy personalization of immunotherapy-based regimens in the neoadjuvant setting of NSCLC.

Published
2022
Full Text
View/download PDF

24. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

Author

Peters, Solange, Felip, Enriqueta, Dafni, Urania, Tufman, Amanda, Guckenberger, Matthias, Álvarez, Ruth, Nadal, Ernest, Becker, Annemarie, Vees, Hansjörg, Pless, Miklos, Martinez-Marti, Alex, Lambrecht, Maarten, Andratschke, Nicolaus, Tsourti, Zoi, Piguet, Anne-Christine, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adrian, Vansteenkiste, Johan, Stahel, Rolf A., and De Ruysscher, Dirk

Published
2021
Full Text
View/download PDF

25. Levels of Arsenic, Cadmium, and Mercury in Urine of Indigenous People Living Close to Oil Extraction Areas in the Peruvian Amazon

Author

O'Callaghan-Gordo, Cristina, Rosales, Jaime, Lizarraga, Pilar, Barclay, Frederica, Okamoto, Tami, Papoulias, Diana M., Espinosa, Ana, Orta-Martinez, Marti, Kogevinas, Manolis, and Astete, John

Subjects
Amazon River region -- Environmental aspects -- Health aspects, Cadmium -- Environmental aspects -- Health aspects, Indigenous peoples -- Health aspects, Arsenic -- Environmental aspects -- Health aspects, Oil fields -- Environmental aspects -- Health aspects, Mercury -- Environmental aspects -- Health aspects, Environmental issues, Health
Abstract

Introduction Oil extraction can lead to long-term harm to the environment and human communities. (1) In the 1970's, oil extraction started in the northern Peruvian Amazon, in the Corrientes, Pastaza, [...]

Published
2023
Full Text
View/download PDF

26. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Author

Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, and Cruz-Bermúdez, Alberto

Published
2020
Full Text
View/download PDF

31. Dynamic changes in circulating tumor <scp>DNA</scp> assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in <scp>NSCLC</scp>

Author

Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip, Institut Català de la Salut, [Carbonell C, Frigola J, Lenza L, Soleda M, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pardo N, Callejo A, Iranzo P, Valdivia A, Cedrés S, Martinez-Marti A, Navarro A] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Priano I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gonzalo-Ruiz J] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Cell-Free Nucleic Acids::Circulating Tumor DNA [CHEMICALS AND DRUGS], Marcadors tumorals, Medicaments antineoplàstics - Ús terapèutic, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], General Medicine, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ácidos nucleicos libres de células::ADN tumoral circulante [COMPUESTOS QUÍMICOS Y DROGAS], Oncology, Genetics, Molecular Medicine, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], Pulmons - Càncer - Tractament
Abstract

Immune checkpoint inhibitors; Liquid biopsy Inhibidores del punto de control inmunitario; Biopsia líquida Inhibidors del punt de control immunitari; Biòpsia líquida Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from this type of treatment. Here, we assessed the value of shallow whole-genome sequencing (sWGS) on plasma samples to monitor ICI benefit. We applied sWGS on cell-free DNA (cfDNA) extracted from plasma samples of 45 patients with metastatic NSCLC treated with ICIs. Over 150 samples were obtained before ICI treatment initiation and at several time points throughout treatment. From sWGS data, we computed the tumor fraction (TFx) and somatic copy number alteration (SCNA) burden and associated them with ICI benefit and clinical features. TFx at baseline correlated with metastatic lesions at the bone and the liver, and high TFx (≥ 10%) associated with ICI benefit. Moreover, its assessment in on-treatment samples was able to better predict clinical efficacy, regardless of the TFx levels at baseline. Finally, for a subset of patients for whom SCNA burden could be computed, increased burden correlated with diminished benefit following ICI treatment. Thus, our data indicate that the analysis of cfDNA by sWGS enables the monitoring of two potential biomarkers—TFx and SCNA burden—of ICI benefit in a cost-effective manner, facilitating multiple serial-sample analyses. Larger cohorts will be needed to establish its clinical potential. This work was partially supported by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945; Grant for Oncology Innovation to the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain); the Insituto de Salud Carlos III through the projects PI20/00987 to EF and PI22/01585 to RA (Co-funded by European Union). The healthcare business of Merck KGaA, Darmstadt, Germany reviewed the manuscript for medical accuracy only before journal submission.

Published
2023
Full Text
View/download PDF

32. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Spicer, Jonathan D, Garassino, Marina C, Wakelee, Heather, Liberman, Moishe, Kato, Terufumi, Tsuboi, Masahiro, Lee, Se-Hoon, Chen, Ke-Neng, Dooms, Christophe, Majem, Margarita, Eigendorff, Ekkehard, Martinengo, Gastón L, Bylicki, Olivier, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Novello, Silvia, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, Samkari, Ayman, Gao, Shugeng, Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, and Zurawski, Bogdan

Abstract

At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis.

Published
2024
Full Text
View/download PDF

34. 120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091

Author

Besse, B., primary, Havel, L., additional, Peters, S., additional, Marreaud, S.I., additional, Jha, N., additional, Oselin, K., additional, Esteban Gonzalez, E., additional, Isla Casado, M.D., additional, Martinez-Marti, A., additional, Faehling, M., additional, Lee, J-S., additional, Luo, Y., additional, Keller, S.M., additional, Dafni, U., additional, Mauer, M.E., additional, Stahel, R.A., additional, O'Brien, M.E.R., additional, Tsuboi, M., additional, and Paz-Ares, L., additional

Published
2023
Full Text
View/download PDF

36. mHealth Platform for the Delivery of Rehabilitation and Physical Exercise at Home for Parkinson’s Disease Patients

Author

Martínez-Martí, Fernando, Villanueva-Mascato, Samanta, Belletoile, Benjamin, Cancela, Jorge, Arredondo, María Teresa, Akan, Ozgur, Series editor, Bellavista, Paolo, Series editor, Cao, Jiannong, Series editor, Coulson, Geoffrey, Series editor, Dressler, Falko, Series editor, Ferrari, Domenico, Series editor, Gerla, Mario, Series editor, Kobayashi, Hisashi, Series editor, Palazzo, Sergio, Series editor, Sahni, Sartaj, Series editor, Shen, Xuemin Sherman, Series editor, Stan, Mircea, Series editor, Xiaohua, Jia, Series editor, Zomaya, Albert Y., Series editor, Guidi, Barbara, editor, Ricci, Laura, editor, Calafate, Carlos, editor, Gaggi, Ombretta, editor, and Marquez-Barja, Johann, editor

Published
2018
Full Text
View/download PDF

42. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

Author

Serna Blasco, R., primary, García Campelo, M.R., additional, Nadal, E., additional, Mediavilla, P., additional, Calvo, V., additional, Gonzalez-Larriba, J.L., additional, Robado de Lope, L., additional, Massutí, B., additional, Martinez-Marti, A., additional, Casal, J., additional, Dómine, M., additional, Cobo, M., additional, Cruz, A., additional, Romero, A., additional, and Provencio, M., additional

Published
2023
Full Text
View/download PDF

43. EP07.04-01 Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results

Author

Pasini, L., primary, Petracci, E., additional, Urbini, M., additional, Felip, E., additional, Stella, F., additional, Tebaldi, M., additional, Azzali, I., additional, Martinez-Marti, A., additional, Pancreach, E., additional, Davoli, F., additional, Salvi, M., additional, Beau, M., additional, Solli, P., additional, Lai, G., additional, Amat, R., additional, Carbonell, C., additional, Delmonte, A., additional, Crinò, L., additional, and Ulivi, P., additional

Published
2023
Full Text
View/download PDF

44. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

Author

Robado de Lope, L., primary, Nadal, E., additional, Calvo, V., additional, González-Larriba, J.L., additional, Insa, A., additional, Martinez-Marti, A., additional, Massutí, B., additional, González, C., additional, Serna Blasco, R., additional, Bosch-Barrera, J., additional, Garcia-Campelo, M.R., additional, Ponce, S., additional, Reguart, N., additional, Bernabé, R., additional, Cobo, M., additional, De Castro, J., additional, Dómine, M., additional, Camps, C., additional, Barneto, I., additional, López-Vivanco, G., additional, Majem, M., additional, Rodríguez-Abreu, D., additional, Palmero, R., additional, Cruz-Bermudez, A., additional, Romero, A., additional, and Provencio, M., additional

Published
2023
Full Text
View/download PDF

45. EP14.04-02 Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p)

Author

Cedres, S., primary, Serna, G., additional, Valdivia, A., additional, Assaf, J.D., additional, Iranzo, P., additional, Callejo, A., additional, Pardo, N., additional, Navarro, A., additional, Martinez-Marti, A., additional, Priano, I., additional, Gonzalez-Medina, A., additional, Fasani, R., additional, Guardia, X., additional, Gonzalo, J., additional, Carbonell, C., additional, Frigola, J., additional, Amat, R., additional, Vivancos, A., additional, Nuciforo, P., additional, and Felip, E., additional

Published
2023
Full Text
View/download PDF

46. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Author

Ponce, Santiago, primary, Cedrés, Susana, additional, Ricordel, Charles, additional, Isambert, Nicolas, additional, Viteri, Santiago, additional, Herrera-Juarez, Mercedes, additional, Martinez-Marti, Alex, additional, Navarro, Alejandro, additional, Lederlin, Mathieu, additional, Serres, Xavier, additional, Zugazagoitia, Jon, additional, Vetrhus, Sylvia, additional, Jaderberg, Magnus, additional, Hansen, Thomas Birkballe, additional, Levitsky, Victor, additional, and Paz-Ares, Luis, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results